Compass Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Compass Therapeutics de winst en omzet met respectievelijk 52.5% en 73.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 52.3% per jaar.

Belangrijke informatie

52.5%

Groei van de winst

52.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.3%
Inkomstengroei	73.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	20 Nov 2024

Recente toekomstige groei-updates

Recent updates

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Winst- en omzetgroeiprognoses

NasdaqCM:CMPX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	68	-69	N/A	-37	7
12/31/2025	5	-66	N/A	-46	7
12/31/2024	1	-49	N/A	-46	7
9/30/2024	1	-48	-48	-48	N/A
6/30/2024	1	-47	-43	-43	N/A
3/31/2024	N/A	-45	-42	-42	N/A
12/31/2023	N/A	-42	-41	-41	N/A
9/30/2023	N/A	-41	-39	-39	N/A
6/30/2023	N/A	-43	-44	-44	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-39	-34	-34	N/A
9/30/2022	N/A	-41	-29	-28	N/A
6/30/2022	N/A	-35	-22	-21	N/A
3/31/2022	N/A	-82	-24	-22	N/A
12/31/2021	N/A	-82	-22	-20	N/A
9/30/2021	N/A	-78	-23	-22	N/A
6/30/2021	N/A	-81	-26	-25	N/A
3/31/2021	N/A	-31	-25	-25	N/A
12/31/2020	N/A	-29	-27	-27	N/A
9/30/2020	N/A	-28	-26	-26	N/A
6/30/2020	N/A	-27	-26	-25	N/A
3/31/2020	N/A	-30	-29	-29	N/A
12/31/2019	N/A	-35	-32	-32	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CMPX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CMPX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CMPX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CMPX ( 73.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van CMPX ( 73.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CMPX naar verwachting over 3 jaar hoog zal zijn

Compass Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 49%

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Price target increased to US$9.46

Price target increased to US$9.67

Price target decreased to US$8.86

Recent updates

Consensus revenue estimates increase by 49%

New minor risk - Profitability

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 32%

Price target decreased by 13% to US$8.00

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Index

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven